Teva launches generic Provigil to treat sleep disorders
Teva Pharmaceutical has launched the authorized generic of Provigil (modafinil), a drug marketed as a wakefulness-promoting agent used to treat sleep disorders, the company announced.
Teva Pharmaceutical has launched the authorized generic of Provigil (modafinil), a drug marketed as a wakefulness-promoting agent used to treat sleep disorders, the company announced.
FDA said patients should be diagnosed by a physician with 1 of the following sleep disorders before taking Provigil: narcolepsy, obstructive sleep apnea/hypopnea syndrome, or shift work sleep disorder.
The drug is not approved for children aged 16 or under.
Among the common side effects of Provigil, according to FDA, are chest pain, mental problems such as depression and suicidal thoughts, and severe skin rash and other allergic reactions.
Provigil is marketed in the United States by Cephalon, a division of Teva.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.
